Abstract:Background: A critical step in tuberculosis (TB) drug development is the Phase 2a early bactericidal activity (EBA) study which informs if a new drug or treatment has short-term activity in humans. The aim of this work was to present a standardized pharmacometric model-based early bactericidal activity analysis workflow and determine sample sizes needed to detect early bactericidal activity or a difference between treatment arms. Methods: Seven different steps were identified and developed for a standardized pharmacometric model-based early bactericidal activity analysis approach. Non-linear mixed effects modeling was applied and different scenarios were explored for the sample size calculations. The sample sizes needed to detect early bactericidal activity given different TTP slopes and associated variability was assessed. In addition, the sample sizes needed to detect effect differences between two treatments given the impact of different TTP slopes, variability in TTP slope and effect differences were evaluated. Results: The presented early bactericidal activity analysis approach incorporates estimate of early bactericidal activity with uncertainty through the model-based estimate of TTP slope, variability in TTP slope, impact of covariates and pharmacokinetics on drug efficacy. Further it allows for treatment comparison or dose optimization in Phase 2a. To detect early bactericidal activity with 80% power and at a 5% significance level, 13 and 8 participants/arm were required for a treatment with a TTP-EBA 0-14 as low as 11 h when accounting for variability in pharmacokinetics and when variability in TTP slope was 104% [coefficient of variation (CV)] and 22%, respectively. Higher sample sizes are required for smaller early bactericidal activity and when pharmacokinetics is not accounted for. Based on sample size determinations to detect a difference between two groups, TTP slope, variability in TTP slope and effect difference between two treatment arms needs to be considered. Conclusion: In conclusion, a robust standardized pharmacometric model-based EBA analysis approach was established in close collaboration between microbiologists, clinicians and pharmacometricians. The work illustrates the importance of accounting for covariates and drug exposure in EBA analysis in order to increase the power of detecting early bactericidal activity for a single treatment arm as well as differences in EBA between treatments arms in Phase 2a trials of TB drug development.

stormTB: A web-based simulator of a murine minimal-PBPK model for anti-tuberculosis treatments.

A minimal PBPK model to accelerate preclinical development of drugs against tuberculosis

121. Improving Predictive Value of Phase 2a TB Drug Development Models Through PET/CT Imaging (nexgen EBA)

A systematic efficacy analysis of tuberculosis treatment with BPaL‐containing regimens using a multiscale modeling approach

Optimizing tuberculosis treatment efficacy: Comparing the standard regimen with Moxifloxacin-containing regimens

Computational pharmacokinetics/pharmacodynamics of rifampin in a mouse tuberculosis infection model

A data and knowledge-driven integrated modeling approach to organ-specific Tuberculosis subtype discovery: A one health paradigm

An open-access dashboard to interrogate the genetic diversity of Mycobacterium tuberculosis clinical isolates

A multi-scale pipeline linking drug transcriptomics with pharmacokinetics predicts in vivo interactions of tuberculosis drugs

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Generation of digital patients for the simulation of tuberculosis with UISS-TB

Use of multiple pharmacodynamic measures to deconstruct the Nix-TB regimen in a short-course murine model of tuberculosis

Physiological modeling of the metaverse of the Mycobacterium tuberculosis β-CA inhibition mechanism

Extrapolation of lung pharmacokinetics of antitubercular drugs from preclinical species to humans using PBPK modelling

A crowd of BashTheBug volunteers reproducibly and accurately measure the minimum inhibitory concentrations of 13 antitubercular drugs from photographs of 96-well broth microdilution plates

Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development

A novel tuberculosis model incorporating a Caputo fractional derivative and treatment effect via the homotopy perturbation method

Antibiotic resistance prediction for Mycobacterium tuberculosis from genome sequence data with Mykrobe

A model-informed preclinical approach for prediction of clinical pharmacodynamic interactions of anti-TB drug combinations

Target Prediction for an Open Access Set of Compounds Active Against Mycobacterium Tuberculosis

One Size Fits All? Not in in Vivo Modeling of Tuberculosis Chemotherapeutics